Threefold Higher Risk for Breast Cancer Death With DCIS Threefold Higher Risk for Breast Cancer Death With DCIS
Compared to the general population, women with ductal carcinoma in situ (DCIS) were more than three times more likely to die from breast cancer; the risk was particularly high for Black women and young women.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 18, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Women with DCIS have 3x the risk of breast cancer death
A new study adds weight to the belief that ductal carcinoma in situ (DCIS)...Read more on AuntMinnie.comRelated Reading: Delayed breast cancer surgery not tied to worse outcomes Preop MRI finds 11% more cancer in women with DCIS Years later, DCIS tied to more imaging but not anxiety Black women still at higher risk of breast cancer death Does imaging modality influence DCIS recurrence? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 17, 2020 Category: Radiology Source Type: news

HCV-Related Liver Cancer Incidence Dropped in US Cohort HCV-Related Liver Cancer Incidence Dropped in US Cohort
The incidence of hepatocellular carcinoma declined after widespread use of direct-acting antiviral therapies to treat hepatitis C, according to findings from a large population-based study.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 16, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Veterinary college team IDs gene that drives ovarian cancer
(Cornell University) scientists at the College of Veterinary Medicine have collaborated on a study that pinpoints which specific genes drive - or delay - high-grade serious ovarian carcinoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 11, 2020 Category: International Medicine & Public Health Source Type: news

First US Trial to Test Aerosolized Chemo in Advanced Cancers First US Trial to Test Aerosolized Chemo in Advanced Cancers
A team of US researchers is investigating whether pressurized intraperitoneal aerosolized chemotherapy (PIPAC) can benefit patients with advanced cancer and peritoneal carcinomatosis.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 10, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Steatohepatitis Biomarkers and HCC After HCV Elimination Steatohepatitis Biomarkers and HCC After HCV Elimination
This study used steatohepatitis-related biomarkers to evaluate the development of hepatocellular carcinoma by patients with chronic hepatitis C who achieved SVR by DAA treatment.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 9, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Radiological Case: Odontogenic Ghost Cell Carcinoma Radiological Case: Odontogenic Ghost Cell Carcinoma
What was the origin of this 10-year-old patient's oral pain and swelling that had been worsening for approximately 1 week? Review the imaging studies in this unusual case.Applied Radiology (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - September 8, 2020 Category: Radiology Tags: Radiology Journal Article Source Type: news

Oncotarget: GATA3 and APOBEC3B are prognostic markers in adrenocortical carcinoma
(Impact Journals LLC) The cover for issue 36 of Oncotarget features Figure 7, 'Knockdown of APOBEC3B is associated with a lower tumor growth in an adrenocortical carcinoma xenograft mouse model,' by Gara, et al. which reported that the role of APOBEC3B in adrenocortical carcinoma and the mechanisms through which its expression is regulated in cancer are not fully understood. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 8, 2020 Category: Cancer & Oncology Source Type: news

Chemotherapy drug more effective when combined with microbubbles
(American Institute of Physics) Hepatocellular carcinoma is usually treated by blocking the flow of blood to the tumor to induce cancer cell death, but the common treatment, transarterial chemoembolization, is invasive and too imprecise to be a local drug delivery method. Aiming to increase the precision, researchers at Tulane University created a treatment that involves vaporizing tiny droplets of perfluorocarbon, a common organic material composed of carbon and fluorine. The method of gas embolization is published in APL Bioengineering. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 8, 2020 Category: International Medicine & Public Health Source Type: news

Sex Disparities in Presentation and Prognosis of HCC Sex Disparities in Presentation and Prognosis of HCC
A new study examines the sex disparities that exist in hepatocellular carcinoma presentation and prognosis. In what ways might these differences impact outcomes?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 2, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Targeted Treatment Tied to Survival for Anaplastic Thyroid Cancer Targeted Treatment Tied to Survival for Anaplastic Thyroid Cancer
With the introduction of targeted treatments for anaplastic thyroid carcinoma, patients have seen significant improvements in survival, according to a new report.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - August 21, 2020 Category: Surgery Tags: Hematology-Oncology News Source Type: news

International team identifies a new regulatory pathway in bladder cancer
(InSilico Medicine) GULP1 regulates the NRF2-KEAP1 signaling axis in urothelial carcinoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 20, 2020 Category: International Medicine & Public Health Source Type: news

Yilmaz Mahshid takes office as CEO of Medivir on 14 September
STOCKHOLM, Aug. 18, 2020 -- (Healthcare Sales & Marketing Network) -- Medivir AB (Nasdaq Stockholm: MVIR) announced today that Dr. Yilmaz Mahshid will assume his position as CEO on September 14, 2020. Uli Hacksell, who has been CEO since October 2018, wil... Biopharmaceuticals, Oncology, Personnel Medivir, hepatocellular carcinoma, liver cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 18, 2020 Category: Pharmaceuticals Source Type: news

GULP1 regulates the NRF2-KEAP1 signaling axis in urothelial carcinoma
Disruption of the KEAP1-NRF2 pathway results in the transactivation of NRF2 target genes, consequently inducing cell proliferation and other phenotypic changes in cancer cells. Here, we demonstrated that GULP1 was a KEAP1-binding protein that maintained actin cytoskeleton architecture and helped KEAP1 to sequester NRF2 in the cytoplasm. In urothelial carcinoma of the bladder (UCB), silencing of GULP1 facilitated the nuclear accumulation of NRF2, led to constitutive activation of NRF2 signaling, and conferred resistance to the platinum drug cisplatin. Knockdown of GULP1 in UCB cells promoted tumor cell proliferation in vitr...
Source: Signal Transduction Knowledge Environment - August 18, 2020 Category: Science Authors: Hayashi, M., Guida, E., Inokawa, Y., Goldberg, R., Reis, L. O., Ooki, A., Pilli, M., Sadhukhan, P., Woo, J., Choi, W., Izumchenko, E., Gonzalez, L. M., Marchionni, L., Zhavoronkov, A., Brait, M., Bivalacqua, T., Baras, A., Netto, G. J., Koch, W., Singh, A Tags: STKE Research Articles Source Type: news

Antibiotic overuse reduces bladder cancer survival rates
(Flinders University) The overprescribing of antibiotics is reducing survival rates in patients with urothelial carcinoma and it needs to be stopped to avoid the serious risk posed by resitant bacterial infections, according to a new medical study. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 16, 2020 Category: Cancer & Oncology Source Type: news

Surgical Delays Not Life-Threatening in Early Breast Cancer
WEDNESDAY, Aug. 12, 2020 -- Surgical delays do not seem to be life-threatening for women with ductal carcinoma in situ (DCIS) or with early-stage estrogen receptor-positive (ER+) breast cancer, according to a study published online Aug. 6 in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 12, 2020 Category: Pharmaceuticals Source Type: news

Analysis of Ugandan cervical carcinomas, an aid for understudied sub-Saharan women
(University of Alabama at Birmingham) Cervical cancer kills more than 300,000 middle-aged women a year, and 19 of the 20 nations with the highest death rates are sub-Saharan countries. Now an international team, including Akinyemi I. Ojesina, M.D., Ph.D., University of Alabama at Birmingham, has published the first comprehensive genomic study of cervical cancers in sub-Saharan Africa, with a focus on tumors from 212 Ugandan patients with cervical cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 10, 2020 Category: Cancer & Oncology Source Type: news

Roche provides update on Phase III study of Tecentriq in combination with paclitaxel for people with metastatic triple-negative breast cancer
Basel, 06 August 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion131 study, evaluating Tecentriq® (atezolizumab) in combination with paclitaxel (chemotherapy), in comparison to placebo plus paclitaxel, did not meet statistical significance on its primary endpoint of progression-fr ee survival (PFS) for the initial (first-line) treatment of people with metastatic triple-negative breast cancer (TNBC), in the PD-L1-positive population. The data for the secondary endpoint of overall survival (OS) showed a negative trend, however, the study was not powered for the secondary endpoi...
Source: Roche Media News - August 6, 2020 Category: Pharmaceuticals Source Type: news

Roche provides update on Phase III study of Tecentriq in combination with paclitaxel for people with metastatic triple-negative breast cancer
Basel, 06 August 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion131 study, evaluating Tecentriq® (atezolizumab) in combination with paclitaxel (chemotherapy), in comparison to placebo plus paclitaxel, did not meet statistical significance on its primary endpoint of progression-fr ee survival (PFS) for the initial (first-line) treatment of people with metastatic triple-negative breast cancer (TNBC), in the PD-L1-positive population. The data for the secondary endpoint of overall survival (OS) showed a negative trend, however, the study was not powered for the secondary endpoi...
Source: Roche Investor Update - August 6, 2020 Category: Pharmaceuticals Source Type: news

SVR From DAA, Interferon-based Treatments for HCV and HCC Risk SVR From DAA, Interferon-based Treatments for HCV and HCC Risk
How does sustained virologic response from direct-acting antiviral and interferon-based treatments impact the risk of developing hepatocellular carcinoma?Journal of Viral Hepatitis (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - August 5, 2020 Category: Infectious Diseases Tags: Gastroenterology Journal Article Source Type: news

Rozlytrek, Roche ’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer
             Basel, 03 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional marketing authorisation for Rozlytrek®(entrectinib) for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, who have no satisfactory t...
Source: Roche Media News - August 3, 2020 Category: Pharmaceuticals Source Type: news

Rozlytrek, Roche ’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer
             Basel, 03 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional marketing authorisation for Rozlytrek®(entrectinib) for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, who have no satisfactory t...
Source: Roche Investor Update - August 3, 2020 Category: Pharmaceuticals Source Type: news

Pembrolizumab too costly as 2nd-line therapy of hepatocellular carcinoma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - August 1, 2020 Category: Drugs & Pharmacology Source Type: news

Researchers ID new target in drive to improve immunotherapy for cancer
FINDINGSResearchers at the UCLA Jonsson Comprehensive Cancer Center and UCLA School of Dentistry  have identified a potential new combination therapy to treat advanced head and neck squamous cell carcinoma, the most common type of head and neck cancer.A study in mice found that using an anti-PD1 immunotherapy drug in combination with PTC209, an inhibitor that targets the protein BMI1, successfully stopped the growth and spread of the cancer, prevented reoccurrences and eliminated cancer stem cells. This is the first preclinical study to provide evidence that targeting BMI1 proteins enhances immunotherapy and eliminate...
Source: UCLA Newsroom: Health Sciences - July 21, 2020 Category: Universities & Medical Training Source Type: news

New special issue on hereditary endocrine tumours published in Endocrine-Related Cancer
The Society for Endocrinology journal,Endocrine-Related Cancer, has recently published a special issue on‘Hereditary endocrine tumours: Current state-of-the-art and research opportunities’. It is guest edited by Steven Waguespack and Constantine Stratakis, and contains eight free-to-read reviews covering topics such as: •New and future perspectives for parathyroid carcinoma•The state of science in medullary thyroid carcinoma: current challenges and unmet needs•Challenges and opportunities in genetic counseling for hereditary endocrine neoplasia syndromes• GPR...
Source: Society for Endocrinology - July 21, 2020 Category: Endocrinology Source Type: news

Researchers ID new target in drive to improve immunotherapy for cancer
(University of California - Los Angeles Health Sciences) UCLA researchers have identified a potential new combination therapy to treat advanced head and neck squamous cell carcinoma, the most common type of head and neck cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 21, 2020 Category: Cancer & Oncology Source Type: news

HCC in Chronic HCV Patients Who Achieved SVR HCC in Chronic HCV Patients Who Achieved SVR
Does achieving SVR with DAAs reduce the incidence of hepatocellular carcinoma in chronic hepatitis C patients, genotype IV with liver cirrhosis and advanced hepatic fibrosis?Journal of Viral Hepatitis (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - July 17, 2020 Category: Infectious Diseases Tags: Gastroenterology Journal Article Source Type: news

Tumor-initiating cells establish an IL-33-TGF-{beta} niche signaling loop to promote cancer progression
Targeting the cross-talk between tumor-initiating cells (TICs) and the niche microenvironment is an attractive avenue for cancer therapy. We show here, using a mouse model of squamous cell carcinoma, that TICs play a crucial role in creating a niche microenvironment that is required for tumor progression and drug resistance. Antioxidant activity in TICs, mediated by the transcription factor NRF2, facilitates the release of a nuclear cytokine, interleukin-33 (IL-33). This cytokine promotes differentiation of macrophages that express the high-affinity immunoglobulin E receptor FcRIα and are in close proximity to TICs. ...
Source: ScienceNOW - July 16, 2020 Category: Science Authors: Taniguchi, S., Elhance, A., Van Duzer, A., Kumar, S., Leitenberger, J. J., Oshimori, N. Tags: Cell Biology, Medicine, Diseases, Online Only r-articles Source Type: news

Oncotarget: The Golgi protein TMEM165 controls migration/invasion for carcinoma
(Impact Journals LLC) The cover for issue 28 of Oncotarget features Figure 5, 'TMEM165 expression levels alters N-linked glycosylation,' by Murali, et al., and reported that the TMEM165 protein was not detected in non-malignant matched breast tissues and was detected in invasive ductal breast carcinoma tissues by mass spectrometry. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 14, 2020 Category: International Medicine & Public Health Source Type: news

Oncotarget: Tumor markers for carcinoma identified by imaging mass spectrometry
(Impact Journals LLC) Volume 11, Issue 28 of Oncotarget features 'Lipid and protein tumor markers for head and neck squamous cell carcinoma identified by imaging mass spectrometry' by Schmidt et, al. which reported that the authors used MALDI imaging mass spectrometry and immunohistochemistry to seek tumor-specific expression of proteins and lipids in HNSCC samples. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 14, 2020 Category: International Medicine & Public Health Source Type: news

Sequential Systemic Treatment in Patients With HCC Sequential Systemic Treatment in Patients With HCC
This study investigated the feasibility and efficacy of sequential systemic treatments with currently available and recently approved drugs for the treatment of hepatocellular carcinoma.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 13, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer
Basel, 13 July 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMagyn050 study showed that the addition of Tecentriq® (atezolizumab) to Avastin® (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of women with newly diagnosed advanced stage ovarian cancer. Topline safety data indicate that safety for Tecentriq in combination with Avastin, paclitaxel and carboplatin was consistent with the known safety profile of the combination.“Ovarian cancer remains one of the most aggressive cancers a...
Source: Roche Investor Update - July 13, 2020 Category: Pharmaceuticals Source Type: news

Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer
Basel, 13 July 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMagyn050 study showed that the addition of Tecentriq® (atezolizumab) to Avastin® (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of women with newly diagnosed advanced stage ovarian cancer. Topline safety data indicate that safety for Tecentriq in combination with Avastin, paclitaxel and carboplatin was consistent with the known safety profile of the combination.“Ovarian cancer remains one of the most aggressive cancers a...
Source: Roche Media News - July 13, 2020 Category: Pharmaceuticals Source Type: news

Viral Exposure Signature Predicts Hepatocellular Carcinoma
Signature can identify hepatocellular carcinoma patients before clinical diagnosis (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 10, 2020 Category: Cancer & Oncology Tags: Gastroenterology, Infections, Oncology, Pathology, Journal, Source Type: news

Viral Exposure Signature Predicts Hepatocellular Carcinoma
FRIDAY, July 10, 2020 -- A viral exposure signature can predict hepatocellular carcinoma (HCC) risk before clinical diagnosis among at-risk patients, according to a study published online June 10 in Cell. Jinping Liu, Ph.D., of the National Cancer... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 10, 2020 Category: Pharmaceuticals Source Type: news

TGen identifies immune effects of drug in aggressive ovarian cancer striking young women
(The Translational Genomics Research Institute) A drug known as SP-2577 could help enable the body's own immune system to attack ovarian cancer, according to a study led by TGen. Published today in the scientific journal PLOS ONE, the study builds on years of research led by Dr. Jeffrey Trent, TGen President and Research Director, into a type of ovarian cancer known as Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT), a cancer that usually strikes girls and young women. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 10, 2020 Category: Cancer & Oncology Source Type: news

Study Supports Changing Classification of Renal Cell Carcinoma Study Supports Changing Classification of Renal Cell Carcinoma
The definition of stage 4 renal cell carcinoma should be expanded to include lymph node-positive stage 3 disease, according to a new study.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 7, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

A 3D biofabricated cutaneous squamous cell carcinoma tissue model
(Impact Journals LLC) The cover for issue 27 of Oncotarget features Figure 4, " (A) Bimodal imaging examples of control and treated tumors (red) before and after the treatment period, " by Browning, et al. and reported that the authors developed a 3-dimensional bioprinted skin model of cutaneous squamous cell carcinoma (cSCC) tumors together with a microscopy assay to test chemotherapeutic effects in tissue. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 7, 2020 Category: Cancer & Oncology Source Type: news

Certain pesticides linked to kidney cancer in agricultural workers
New findings from the Agricultural Health Study suggest exposure to certain pesticides may increase risk of renal cell carcinoma. (read more) (Source: Environmental Factor - NIEHS Newsletter)
Source: Environmental Factor - NIEHS Newsletter - July 6, 2020 Category: Environmental Health Source Type: news

Liquid Biopsy Promising in Spotting Kidney Cancer Liquid Biopsy Promising in Spotting Kidney Cancer
An assay employing plasma and urine cell-free DNA methylomes is capable of classifying patients across all stages of renal-cell carcinoma, according to preliminary studies.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - July 2, 2020 Category: Pathology Tags: Hematology-Oncology News Source Type: news

FDA approves avelumab for urothelial carcinoma maintenance treatment
Hematology / Oncology News Bursts (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - July 1, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Bavencio as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Rockland, MA and New York, US, JUNE 30, 2020– EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 30, 2020 Category: Drugs & Pharmacology Source Type: news

New compounds from starfish of Kuril basin show efficacy against cancer cells.
(Far Eastern Federal University) Russian scientists from Far Eastern Federal University (FEFU), G. B. Elyakov Pacific Institute of Bioorganic Chemistry (PIBOC FEB RAS), and A.V. Zhirmunsky National Scientific Center for Marine Biology (NSCMB FEB RAS) have discovered four new steroid substances which target cells of human breast cancer, and colorectal carcinoma. They were extracted from the starfish Ceramaster patagonicus, a Kuril basin seabed dweller. A related article appears in Marine Drugs. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 26, 2020 Category: Cancer & Oncology Source Type: news

FDA approves pembrolizumab for cutaneous squamous cell carcinoma
Hematology /Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 24, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Preop MRI finds 11% more cancer in women with DCIS
Preoperative breast MRI finds 11% more cancer in women with ductal carcinoma...Read more on AuntMinnie.comRelated Reading: Years later, DCIS tied to more imaging but not anxiety Who gets breast cancer treatment during a pandemic? Breast MRI works as presurgical tool 10-minute breast MRI scan beats DBT for invasive cancer Does imaging modality influence DCIS recurrence? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 24, 2020 Category: Radiology Source Type: news

FDA Approves Merck ’s Keytruda (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) that is Not Curable by Surgery or Radiation
KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, as monotherapy for the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 24, 2020 Category: Drugs & Pharmacology Source Type: news

Oncotarget: Bacteriome and mycobiome and bacteriome-mycobiome interactions
(Impact Journals LLC) Volume 11 Issue 25 of @Oncotarget reported that the authors aimed to characterize the bacteriome, mycobiome, and mycobiome-bacteriome interactions of oral wash in Head and neck squamous cell carcinoma, or HNSCC, patients and to determine if they are distinct from those of the oral wash of matched non-Head and neck squamous cell carcinoma patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 23, 2020 Category: Cancer & Oncology Source Type: news

Aspergilloma Complicating Metastatic Renal Carcinoma in the Left Main Bronchus
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - June 22, 2020 Category: Respiratory Medicine Authors: MeganB Source Type: news

Aspergillosis in the Presence of Squamous Cell Carcinoma
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - June 21, 2020 Category: Respiratory Medicine Authors: MeganB Source Type: news

Carcinoma in Situ of the Bladder: Why Is It Underdetected? Carcinoma in Situ of the Bladder: Why Is It Underdetected?
The diagnosis of carcinoma in situ of the bladder remains challenging. Could certain new diagnostic techniques improve the detection rate?Current Opinion in Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 18, 2020 Category: Consumer Health News Tags: Urology Journal Article Source Type: news